ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Takeda is paying Tesaro $100 million up front for the rights in certain countries to the PARP inhibitor niraparib, which received FDA approval in April to treat recurrent ovarian cancer. Takeda gains broad rights to develop niraparib in Japan and to pursue the compound as a prostate cancer treatment in South Korea, Taiwan, Russia, and Australia. Tesaro could see another $240 million in milestone payments if niraparib is approved in those markets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X